These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 23525511

  • 1. Comparison of the systemic bioavailability of mometasone furoate after oral inhalation from a mometasone furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate dry-powder inhaler in patients with chronic obstructive pulmonary disease.
    Kosoglou T, Hubbell J, Xuan F, Cutler DL, Meehan AG, Kantesaria B, Wittmer BA.
    Int J Chron Obstruct Pulmon Dis; 2013; 8():107-16. PubMed ID: 23525511
    [Abstract] [Full Text] [Related]

  • 2. An evaluation of the systemic bioavailability of mometasone furoate (MF) after oral inhalation from a MF/formoterol fumarate metered-dose inhaler versus an MF dry-powder inhaler in healthy subjects.
    Kosoglou T, Hubbell J, Kantesaria B, Hanson ME, Cutler DL.
    Clin Pharmacol Drug Dev; 2014 May; 3(3):229-34. PubMed ID: 27128613
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of potential for pharmacokinetic interaction between mometasone furoate and formoterol fumarate after oral inhalation from a fixed-dose combination metered-dose inhaler device.
    Kosoglou T, Hubbell J, Johnson-Levonas AO, Yunan M, Kantesaria BS, Cutler DL.
    Clin Pharmacol Drug Dev; 2014 May; 3(3):222-8. PubMed ID: 27128612
    [Abstract] [Full Text] [Related]

  • 4. Hypothalamic-pituitary-adrenal axis effects of mometasone furoate/formoterol fumarate vs fluticasone propionate/salmeterol administered through metered-dose inhaler.
    Kosoglou T, Hubbell J, Cutler DL, Johnson-Levonas AO, Xu D, Kantesaria BS, Kim K, Miller SD.
    Chest; 2013 Dec; 144(6):1795-1802. PubMed ID: 24077095
    [Abstract] [Full Text] [Related]

  • 5. Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD.
    Doherty DE, Tashkin DP, Kerwin E, Knorr BA, Shekar T, Banerjee S, Staudinger H.
    Int J Chron Obstruct Pulmon Dis; 2012 Dec; 7():57-71. PubMed ID: 22334769
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial.
    Tashkin DP, Doherty DE, Kerwin E, Matiz-Bueno CE, Knorr B, Shekar T, Banerjee S, Staudinger H.
    Int J Chron Obstruct Pulmon Dis; 2012 Dec; 7():43-55. PubMed ID: 22334768
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials.
    Tashkin DP, Doherty DE, Kerwin E, Matiz-Bueno CE, Knorr B, Shekar T, Gates D, Staudinger H.
    Int J Chron Obstruct Pulmon Dis; 2012 Dec; 7():73-86. PubMed ID: 22334770
    [Abstract] [Full Text] [Related]

  • 8. Bronchodilation with mometasone furoate/formoterol fumarate administered by metered-dose inhaler with and without a spacer in children with persistent asthma.
    Berger WE, Bensch GW, Weinstein SF, Skoner DP, Prenner BM, Shekar T, Nolte H, Teper AA.
    Pediatr Pulmonol; 2014 May; 49(5):441-50. PubMed ID: 24019197
    [Abstract] [Full Text] [Related]

  • 9. Dose-dependent anti-inflammatory effect of inhaled mometasone furoate/formoterol in subjects with asthma.
    Nolte H, Pavord I, Backer V, Spector S, Shekar T, Gates D, Nair P, Hargreave F.
    Respir Med; 2013 May; 107(5):656-64. PubMed ID: 23490226
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology after single and chronic dosing in patients with COPD.
    Dunn LJ, Kerwin EM, DeAngelis K, Darken P, Gillen M, Dorinsky P.
    Pulm Pharmacol Ther; 2020 Feb; 60():101873. PubMed ID: 31841699
    [Abstract] [Full Text] [Related]

  • 11. Long-term safety of mometasone furoate/formoterol combination for treatment of patients with persistent asthma.
    Maspero JF, Nolte H, Chérrez-Ojeda I, P04139 Study Group.
    J Asthma; 2010 Dec; 47(10):1106-15. PubMed ID: 20874458
    [Abstract] [Full Text] [Related]

  • 12. A Randomized, Double-Blind, Double-Dummy Study of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Relative to Umeclidinium/Vilanterol Dry Powder Inhaler in COPD.
    Maltais F, Ferguson GT, Feldman GJ, Deslee G, Bourdin A, Fjällbrant H, Siwek-Posłuszna A, Jenkins MA, Martin UJ.
    Adv Ther; 2019 Sep; 36(9):2434-2449. PubMed ID: 31267366
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics of Salbutamol Delivered from the Unit Dose Dry Powder Inhaler: Comparison with the Metered Dose Inhaler and Diskus Dry Powder Inhaler.
    Moore A, Riddell K, Joshi S, Chan R, Mehta R.
    J Aerosol Med Pulm Drug Deliv; 2017 Jun; 30(3):164-172. PubMed ID: 28170282
    [Abstract] [Full Text] [Related]

  • 14. Randomized study of the effects of Aerochamber Plus® Flow-Vu® on the efficacy, pharmacokinetics and safety of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler in patients with chronic obstructive pulmonary disease.
    Fakih F, Spangenthal S, Sigal B, Darken P, Maes A, Siddiqui S, Gillen M, Reisner C, Martin UJ.
    Respir Med; 2018 May; 138():74-80. PubMed ID: 29724397
    [Abstract] [Full Text] [Related]

  • 15. Dose counter performance of mometasone furoate/formoterol inhalers in subjects with asthma or COPD.
    Weinstein C, Staudinger H, Scott I, Amar NJ, LaForce C.
    Respir Med; 2011 Jul; 105(7):979-88. PubMed ID: 21398104
    [Abstract] [Full Text] [Related]

  • 16. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial.
    Ferguson GT, Rabe KF, Martinez FJ, Fabbri LM, Wang C, Ichinose M, Bourne E, Ballal S, Darken P, DeAngelis K, Aurivillius M, Dorinsky P, Reisner C.
    Lancet Respir Med; 2018 Oct; 6(10):747-758. PubMed ID: 30232048
    [Abstract] [Full Text] [Related]

  • 17. Patient satisfaction with a pressurized metered-dose inhaler with an integrated dose counter containing a fixed-dose mometasone furoate/formoterol combination.
    LaForce C, Weinstein C, Nathan RA, Weinstein SF, Staudinger H, Meltzer EO.
    J Asthma; 2011 Aug; 48(6):625-31. PubMed ID: 21726121
    [Abstract] [Full Text] [Related]

  • 18. Long-term safety of mometasone furoate administered via a dry powder inhaler in children: Results of an open-label study comparing mometasone furoate with beclomethasone dipropionate in children with persistent asthma.
    Noonan M, Leflein J, Corren J, Staudinger H.
    BMC Pediatr; 2009 Jul 13; 9():43. PubMed ID: 19594937
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler in Chinese Patients with COPD: A Subgroup Analysis of KRONOS.
    Wang C, Yang T, Kang J, Chen R, Zhao L, He H, Assam PN, Su R, Bourne E, Ballal S, DeAngelis K, Dorinsky P.
    Adv Ther; 2020 Apr 13; 37(4):1591-1607. PubMed ID: 32152869
    [Abstract] [Full Text] [Related]

  • 20. A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease.
    Reisner C, Fabbri LM, Kerwin EM, Fogarty C, Spangenthal S, Rabe KF, Ferguson GT, Martinez FJ, Donohue JF, Darken P, St Rose E, Orevillo C, Strom S, Fischer T, Golden M, Dwivedi S.
    Respir Res; 2017 Jan 06; 18(1):8. PubMed ID: 28061907
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.